Dalcetrapib: meta-analysis of COVID-19 studies

All studies   Mortality   Ventilation   Hospitalization   Serious outcomes   RCTs   RCT mortality   All outcomes  
Meta-analysis1 study · 208 patientsc19early.org

Dalcetrapib for COVID-19

Serious outcome risk
Dalcetrapib
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−134%
Mortality (1)−134%
Ventilation (1)−134%
Hospitalization (1)−37%
RCTs (1)−134%
Early (1)−134%
00.511.5+
← Dalcetrapib
reduces riskIncreased
risk →
c19early.org
October 2026

Dalcetrapib COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Kallend (DB RCT)−134%2.34 · 0.10–56.64death1/1550/53
Early treatment−134%2.34 · 0.10–56.641/1550/53134% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.61
All studies−134%2.34 · 0.10–56.641/1550/53134% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6100.511.52+
Rotate screen for more detailsIncrease width for more details
← Dalcetrapib
reduces riskDalcetrapib
increases risk →
c19early.org
October 2026

Dalcetrapib COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Kallend (DB RCT)−134%2.34 · 0.10–56.641/1550/53
Early treatment−134%2.34 · 0.10–56.641/1550/53134% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.61
All studies−134%2.34 · 0.10–56.641/1550/53134% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6100.511.52+
Rotate screen for more detailsIncrease width for more details
← Dalcetrapib
reduces riskDalcetrapib
increases risk →
c19early.org
October 2026

Dalcetrapib COVID-19 mechanical ventilation results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Kallend (DB RCT)−134%2.34 · 0.10–56.641/1550/53
Early treatment−134%2.34 · 0.10–56.641/1550/53134% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.61
All studies−134%2.34 · 0.10–56.641/1550/53134% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6100.511.52+
Rotate screen for more detailsIncrease width for more details
← Dalcetrapib
reduces riskDalcetrapib
increases risk →
c19early.org
October 2026

Dalcetrapib COVID-19 hospitalization results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Kallend (DB RCT)−37%1.37 · 0.30–6.24hosp.8/1552/53
Early treatment−37%1.37 · 0.30–6.248/1552/5337% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.7
All studies−37%1.37 · 0.30–6.248/1552/5337% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.700.511.52+
Rotate screen for more detailsIncrease width for more details
← Dalcetrapib
reduces riskDalcetrapib
increases risk →
c19early.org
October 2026

Dalcetrapib COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Kallend (DB RCT)−134%2.34 · 0.10–56.64death1/1550/53
Early treatment−134%2.34 · 0.10–56.641/1550/53134% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.61
All studies−134%2.34 · 0.10–56.641/1550/53134% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6100.511.52+
Rotate screen for more detailsIncrease width for more details
← Dalcetrapib
reduces riskDalcetrapib
increases risk →
c19early.org
October 2026

Dalcetrapib COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Kallend (DB RCT)−134%2.34 · 0.10–56.64death1/1550/53
Early treatment−134%2.34 · 0.10–56.641/1550/53134% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.61
All studies−134%2.34 · 0.10–56.641/1550/53134% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6100.511.52+
Rotate screen for more detailsIncrease width for more details
← Dalcetrapib
reduces riskDalcetrapib
increases risk →
c19early.org
October 2026

Dalcetrapib COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Kallend (DB RCT)−134%2.34 · 0.10–56.641/1550/53
Early treatment−134%2.34 · 0.10–56.641/1550/53134% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.61
All studies−134%2.34 · 0.10–56.641/1550/53134% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6100.511.52+
Rotate screen for more detailsIncrease width for more details
← Dalcetrapib
reduces riskDalcetrapib
increases risk →